U.S. Supreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit
The U.S. Supreme Court has issued an order preserving access to mifepristone, a key medication used in abortions, while legal challenges continue. The decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail-order distribution of the drug. This ruling ensures that women can continue obtaining mifepristone through pharmacies and telehealth services without interruption, at least until the case proceeds further, potentially into next year. The emergency stay was granted in favor of the drug's manufacturers, Danco Laboratories and GenBioPro, who appealed a federal appeals court decision. Justices Clarence Thomas and Samuel Alito dissented, arguing against the manufacturers' actions. The lawsuit, initiated by Louisiana, challenges FDA regulations approved in 2000 and modified five years ago to allow remote prescribing. Anti-abortion groups are pressuring the Trump administration to expedite reviews aimed at restricting access, citing safety concerns despite FDA affirmations of the drug's efficacy. This development occurs four years after the overturning of Roe v. Wade, highlighting ongoing national debates over reproductive rights and federal regulatory authority.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection